Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05344_nanopub.RAOs2Q3xC5J-7Nns9P_xZ8C7pQ3gdNtj62eLdvS-Q3v5Q#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05344 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05344 label "NT-501 [drugbank:DB05344]" assertion.
- drugbank:DB05344 seeAlso DB05344 assertion.
- drugbank:DB05344 description "NT-501 is Neurotech's lead product which is in two Phase II/III clinical trials for the treatment of visual loss associated with retinitis pigmentosa and a Phase II trial for the treatment of the dry form of age-related macular degeneration. Neurotech is also evaluating other factors that can be used with its proprietary delivery technology, Encapsulated Cell Technology (ECT), to treat additional retinal diseases." assertion.
- drugbank:DB05344 identifier "drugbank:DB05344" assertion.
- drugbank:DB05344 title "NT-501" assertion.
- drugbank:DB05344 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05344 drugbank_vocabulary:drugbank-id "DB05344" assertion.
- drugbank:DB05344 bio2rdf_vocabulary:x-identifiers.org DB05344 assertion.
- drugbank:DB05344 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05344" assertion.
- drugbank:DB05344 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05344 bio2rdf_vocabulary:identifier "DB05344" assertion.